FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development
Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.
FUJIFILM Irvine Scientific has introduced BalanCD Gal Supplement. The new formula has been developed to increase galactosylation in biotherapeutic development, to help achieve desired glycan profiles for improved product quality and antibody efficacy.
Glycosylation is a critical aspect in development and optimization of protein-based therapeutics. The type and level of glycosylation can significantly affect antibody binding, function, and therapeutic efficacy. Galactosylation (the glycosylation of galactose) is a key method for controlling product quality due to the significant impact it has on antibody function, and the ability to control levels of galactosylation through the cell culture medium.
BalanCD Gal Supplement is a chemically defined, animal component-free formula designed to increase N-linked galactosylation with a scalable protocol, offering researchers a simple method to control the process through the cell culture medium. The supplement is effective at low concentrations and is compatible with any basal growth medium.
BalanCD Gal Supplement has been developed as part of the BalanCD CHO media platform - an extended portfolio of chemically defined, animal component-free growth and feed media formulated using Rational Culture Media Design. This multidimensional approach uses sequential, complementary development methods to leverage FUJIFILM Irvine Scientific scientists’ expertise in the effects of components and process parameters. The result is a media platform that delivers the precise combination of nutrients to maximize productivity, growth, and viability of CHO cell lines.
“The BalanCD Gal Supplement has been designed to incorporate seamlessly into our BalanCD media portfolio, providing researchers in biotherapeutic development with a holistic, efficient growth and production platform. Developed by our expert research and development group, the new supplement supports scientists in streamlining workflows, ultimately to advance emerging therapies,” said Robert Newman PhD, Chief Scientific Officer, FUJIFILM Irvine Scientific.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance